Cargando…
LB2305. Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial
BACKGROUND: Deferral of antiretroviral therapy (ART) initiation until CD4 count < 350 cells/μL in people with CD4 > 500 increases risk of AIDS and serious non-AIDS (SNA) conditions. Evidence from randomized trials is lacking to assess the extent to which ongoing excess risk due to having defer...
Autores principales: | Babiker, Abdel G, Lundgren, Jens, Sharma, Shweta, Grund, Birgit, Phillips, Andrew, Kan, Virginia L, Matthews, Gail, Klingman, Karin L, Neaton, James D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752716/ http://dx.doi.org/10.1093/ofid/ofac492.1895 |
Ejemplares similares
-
When to start antiretroviral therapy: the need for an evidence base during early HIV infection
por: Lundgren, Jens D, et al.
Publicado: (2013) -
Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial
por: Baker, Jason V, et al.
Publicado: (2017) -
Regulatory effect of paraprobiotic Lactobacillus gasseri CP2305 on gut environment and function
por: Sugawara, Tomonori, et al.
Publicado: (2016) -
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy
por: Grund, Birgit, et al.
Publicado: (2016) -
PReS-FINAL-2305: Erythema multiforme in a child with lupus - what's in a name?
por: Khubchandani, R, et al.
Publicado: (2013)